Growth Metrics

Emergent BioSolutions (EBS) Net Margin (2016 - 2026)

Emergent BioSolutions has reported Net Margin over the past 15 years, most recently at 4.36% for Q1 2026.

  • For Q1 2026, Net Margin fell 2625.0% year-over-year to 4.36%; the TTM value through Mar 2026 reached 1.27%, up 1603.0%, while the annual FY2025 figure was 7.08%, 2534.0% up from the prior year.
  • Net Margin for Q1 2026 was 4.36% at Emergent BioSolutions, up from 36.72% in the prior quarter.
  • Over five years, Net Margin peaked at 39.07% in Q3 2024 and troughed at 566.2% in Q2 2024.
  • A 5-year average of 53.84% and a median of 17.9% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: tumbled -48884bps in 2024 and later surged 55768bps in 2025.
  • Year by year, Net Margin stood at 20.29% in 2022, then rose by 12bps to 17.9% in 2023, then rose by 10bps to 16.08% in 2024, then crashed by -128bps to 36.72% in 2025, then soared by 112bps to 4.36% in 2026.
  • Business Quant data shows Net Margin for EBS at 4.36% in Q1 2026, 36.72% in Q4 2025, and 22.15% in Q3 2025.